329 related articles for article (PubMed ID: 27100443)
1. The Presence of White Matter Lesions Is Associated With the Fibrosis Severity of Nonalcoholic Fatty Liver Disease.
Petta S; Tuttolomondo A; Gagliardo C; Zafonte R; Brancatelli G; Cabibi D; Cammà C; Di Marco V; Galvano L; La Tona G; Licata A; Magliozzo F; Maida C; Marchesini G; Merlino G; Midiri M; Parrinello G; Torres D; Pinto A; Craxì A
Medicine (Baltimore); 2016 Apr; 95(16):e3446. PubMed ID: 27100443
[TBL] [Abstract][Full Text] [Related]
2. Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).
Gerhardt F; Petroff D; Blank V; Böhlig A; van Bömmel F; Wittekind C; Berg T; Karlas T; Wiegand J
Scand J Gastroenterol; 2020 Jun; 55(6):706-711. PubMed ID: 32476514
[No Abstract] [Full Text] [Related]
3. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease.
Costa-Silva L; Ferolla SM; Lima AS; Vidigal PVT; Ferrari TCA
Eur J Radiol; 2018 Jan; 98():82-89. PubMed ID: 29279175
[TBL] [Abstract][Full Text] [Related]
4. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.
Leite NC; Villela-Nogueira CA; Pannain VL; Bottino AC; Rezende GF; Cardoso CR; Salles GF
Liver Int; 2011 May; 31(5):700-6. PubMed ID: 21457442
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
Shelley K; Articolo A; Luthra R; Charlton M
BMC Gastroenterol; 2023 May; 23(1):160. PubMed ID: 37208593
[TBL] [Abstract][Full Text] [Related]
6. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
[TBL] [Abstract][Full Text] [Related]
7. Ultrasonographic Nonalcoholic Fatty Pancreas Is Associated with Advanced Fibrosis in NAFLD: A Retrospective Analysis.
Rosenblatt R; Mehta A; Snell D; Hissong E; Kierans AS; Kumar S
Dig Dis Sci; 2019 Jan; 64(1):262-268. PubMed ID: 30269271
[TBL] [Abstract][Full Text] [Related]
8. Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD.
Caussy C; Hsu C; Singh S; Bassirian S; Kolar J; Faulkner C; Sinha N; Bettencourt R; Gara N; Valasek MA; Schnabl B; Richards L; Brenner DA; Hofmann AF; Loomba R
Aliment Pharmacol Ther; 2019 Jan; 49(2):183-193. PubMed ID: 30506692
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.
Pelusi S; Cespiati A; Rametta R; Pennisi G; Mannisto V; Rosso C; Baselli G; Dongiovanni P; Fracanzani AL; Badiali S; Maggioni M; Craxi A; Fargion S; Prati D; Nobili V; Bugianesi E; Romeo S; Pihlajamaki J; Petta S; Valenti L
Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2310-2319.e6. PubMed ID: 30708111
[TBL] [Abstract][Full Text] [Related]
10. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
[TBL] [Abstract][Full Text] [Related]
11. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.
Alkhouri N; Johnson C; Adams L; Kitajima S; Tsuruno C; Colpitts TL; Hatcho K; Lawitz E; Lopez R; Feldstein AE
PLoS One; 2018; 13(8):e0202226. PubMed ID: 30161179
[TBL] [Abstract][Full Text] [Related]
12. Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis.
Loomba R; Jain A; Diehl AM; Guy CD; Portenier D; Sudan R; Singh S; Faulkner C; Richards L; Hester KD; Okada L; Li XJ; Mimms L; Abdelmalek MF
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1867-1876.e3. PubMed ID: 30448594
[TBL] [Abstract][Full Text] [Related]
13. The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD).
D'Ambrosio R; Campi I; Maggioni M; Perbellini R; Giammona E; Stucchi R; Borghi M; Degasperi E; De Silvestri A; Persani L; Fugazzola L; Lampertico P
PLoS One; 2021; 16(4):e0249614. PubMed ID: 33822817
[TBL] [Abstract][Full Text] [Related]
14. Non-obese patients with nonalcoholic fatty liver disease may use a lower liver stiffness cut-off to assess fibrosis stages.
Shi YW; Wang QY; Zhao XY; Sun YM; Kong YY; Ou XJ; Jia JD; Wu SS; You H
J Dig Dis; 2020 May; 21(5):279-286. PubMed ID: 32336033
[TBL] [Abstract][Full Text] [Related]
15. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
16. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease.
Petta S; Ciminnisi S; Di Marco V; Cabibi D; Cammà C; Licata A; Marchesini G; Craxì A
Aliment Pharmacol Ther; 2017 Feb; 45(4):510-518. PubMed ID: 28028821
[TBL] [Abstract][Full Text] [Related]
17. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
[TBL] [Abstract][Full Text] [Related]
18. Periodontitis is associated with significant hepatic fibrosis in patients with non-alcoholic fatty liver disease.
Alazawi W; Bernabe E; Tai D; Janicki T; Kemos P; Samsuddin S; Syn WK; Gillam D; Turner W
PLoS One; 2017; 12(12):e0185902. PubMed ID: 29220367
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
[TBL] [Abstract][Full Text] [Related]
20. Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis.
Chang D; Truong E; Mena EA; Pacheco F; Wong M; Guindi M; Todo TT; Noureddin N; Ayoub W; Yang JD; Kim IK; Kohli A; Alkhouri N; Harrison S; Noureddin M
Hepatology; 2023 Feb; 77(2):546-557. PubMed ID: 35809234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
